Lupin Reaches Quarter-Of-A-Billion Dollar Deal Over Glumetza Antitrust Claims

Antitrust Class Action Filed In 2019; Bausch Health Settled Earlier In September

 
• By Dean Rudge
  
Gavel
Lupin said it disputed the claims but acknowledged "increased uncertainty." • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business